MK-5160

MK-5160 is a novel insulin receptor partial agonist (IRPA) developed as a potential basal insulin therapy for diabetes mellitus. It is designed as a dimer of native insulin connected via chemical linkers, resulting in partial activation of the insulin receptor compared to native insulin. This mechanism aims to provide effective glucose lowering while reducing the risk of hypoglycemia associated with traditional insulins. Preclinical studies demonstrated that IRPAs like MK-5160 can normalize plasma glucose levels and have a prolonged duration of action, making them suitable for once-daily dosing. Clinical development focused on type 1 and type 2 diabetes mellitus, with phase 1 trials completed[1][2][3][4][5].